Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Betacarotene
Alvetra u. Werfft GmbH
QA11CA02
Betacarotene
10 milligram(s)/millilitre
Emulsion for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Cattle, Pigs
betacarotene
Vitamins and minerals
Authorised
2016-02-12
Health Products Regulatory Authority 07 September 2020 CRN009HCL Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Carofertin 10 mg/ml Emulsion for injection for cattle and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: ACTIVE SUBSTANCE: Betacarotene 10.00 mg EXCIPIENTS: Benzyl alcohol (E1519) 10.00 mg Ascorbyl palmitate (E304) 0.12 mg All‐rac‐α‐tocopherol 0.10 mg For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Emulsion for injection. Clear, dark red emulsion. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle (cows/heifers), pig (sows). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the prevention and treatment of beta‐carotene deficiency and beta‐carotene deficiency related fertility disorders, which can arise during phases of insufficient nutritional supply. 4.3 CONTRAINDICATIONS Do not use in newborn animals because of the presence of benzyl alcohol. Do not use in known cases of hypersensitivity to macrogol stearate, or in case of hypersensitivity to the active substance or to any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals None Special precautions to be taken by the person administering the veterinary medicinal product to animals Care should be taken to avoid accidental self‐injection. In case of accidental self‐injection, seek medical advice immediately and show the package leaflet or the label to the physician. People with known hypersensitivity to betacarotene or to any of the excipients should administer the veterinary medicinal product with caution. Wash hands after use. Health Products Regulatory Authority 07 September 2020 CRN009HCL Page 2 of 4 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) Swelling at the site of the injection occurs very rarely.. This usually resolves without t Read the complete document